Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?

    ... patients. In fact, hypomethylating agents (HMA) like azacitidine have been successfully used in clinical trials and achieved ... agent HMA treatment. Currently, combination therapies of azacitidine with lenalidomide appear to be promising thus making them ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

    ... months even in the presence of continuous therapy with azacitidine (AZA). Whether p53 expression status known to confer ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Expression of nucleoside metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

    ... The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Azacitidine adverse effects in patients with myelodysplastic syndromes

    ... Azacitidine is now considered one of the standard-of-care agents for ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Adverse effects of azacitidine: onset, duration, and treatment

    ... with survivals of close to only 1 year. The use of azacitidine , a DNA methyltransferase inhibitor, in this group of patients ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

    ... This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nurses

    ... von Riedemann S, Kurtin S; Canadian Nurses Working Group on Azacitidine in MDS Original ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry

    Journal Title:  Leukemia Primary Author:  Dinmohamed AG Author(s):  Dinmohame...

    Research Article last updated 07/20/2018 - 5:15pm.